WuXi Chemistry

Join our upcoming webinar to learn about research strategies for the discovery of targeted protein degraders. Using an event-driven pharmacology approach, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. This technology is enabling researchers to pursue targets that were previously considered undruggable and to address the resistance issue of small molecule inhibitors. Since 2016, WuXi AppTec has built a comprehensive TPD discovery service platform to investigate the full functional cycle of protein degraders - from binary/ternary complex formation to target ubiquitination and degradation. Don’t miss your chance to ask questions to our experts! Click this link 👇to register for our webinar: https://lnkd.in/egx4kZAy

Service Spotlight: Do you have molecules in the preclinical stage? Our #IND Enabling Pre-formulation Package (IEPP) can complete #developability assessment and develop the most suitable formulation for your molecule within 8-12 weeks. All testing, including the animal PK study, will be completed and the formulation will be ready for IND filing. Explore our IEPP service: https://lnkd.in/eXb5UB2g #WuXiSTA #formulation #bioavailability #IND #CRDMO #DrugProduct

Missed our recent discussion on Overcoming Key Challenges in #PROTAC Drug Development? Watch the webinar on demand here: https://lnkd.in/eA29G_nx Our speakers presented a compelling case study, demonstrating how we accelerated a PROTAC drug candidate with a complex 24-step synthetic process, low yield, and oral bioavailability (F < 1%) to IND filing within just 12 months. For inquiries, contact us at [email protected]

We're delighted to announce that WuXi AppTec has been included in the #FTSE4Good Index Series for the second consecutive year!    This recognition demonstrates our exceptional performance in environmental, social, and governance (#ESG) practices driven by our commitment to advancing #sustainability and enabling #innovation for a healthier world. An independent assessment by FTSE Russell, An LSEG Business, a global index and data provider, scored WuXi AppTec above global industry standards.   Through our unique CRDMO and CTDMO business models, we continue to support customers’ needs by developing and delivering innovative new therapies to patients worldwide, working together towards a better and more sustainable future.

At WuXi TIDES, we offer full-spectrum CRDMO services for #peptides and #oligonucleotides, covering discovery, API process R&D, formulation development, and manufacturing. Our comprehensive capabilities span both drug substance and drug product development across various modalities, including siRNA, sgRNA, ASO, PMO, and conjugates like POC, PDC, RDC, and PPMO. Visit our newly designed website https://lnkd.in/g6AmChYd today to see how we can be your trusted partner in pharmaceutical innovation. Explore our global sites and learn more about our integrated CRDMO platform dedicated to advancing life-changing therapies. #WuXiTIDES #CRDMO #peptides #oligonucleotides

WuXi TIDES Online Shop now locally warehouses select products in both the US and Europe! Let us know which #WuXiTIDES #Catalog products you need in stock for next day delivery. For a full inventory list, reach out to [email protected] to learn more.   Up to 30% Off Select Amidite Products – Shop Now: https://lnkd.in/exwmTMhx

Explore our 2023 #ESG Report, showcasing our continued integration of ESG priorities into our strategy and operations. We promote business practices that are environmentally sustainable, socially impactful, and aligned with robust governance standards. Built on integrity and high ethical standards, we strive to deliver exceptional services and customer experiences while being deeply committed to enabling innovation and improving lives. Explore our ESG progress in the full report here: https://lnkd.in/e3tAJb7m #ESG #Sustainability #CorporateResponsibility WuXi AppTec 

#siRNAs, a subclass of #oligonucleotides, can selectively silence disease-causing genes, offering new therapeutic opportunities. #GalNAc-siRNA conjugates have emerged as a key strategy in cancer therapy due to their targeting capabilities. Read this WuXi TIDES case study to see how our integrated CMC services managed oligonucleotide synthesis, GalNAc supply, formulation development, manufacturing, and analytical support. Using innovative conjugation chemistry and tailored analytical studies, we significantly improved crude purity and yield, delivering two siRNA-GalNAc CMC packages ready for IND submission within 14 months. Visit our website: https://lnkd.in/g6AmChYd #WuXiTIDES #siRNAs #oligonucleotides #therapies

Today is the final day to register for our webinar on overcoming key challenges in PROTAC drug development. Secure your spot now and join us live tomorrow for expert insights and interactive discussions. We can't wait to see you there!

Technology Spotlight: Our #Changzhou site has launched a new Simulated Moving Bed Chromatography (SMB) system, further expanding our enabling technology portfolio to better serve your API purification needs. Compared to Prep-HPLC, SMB is more solvent-efficient and offers higher production throughput. Designed for large-scale chiral compound separation, SMB ensures the stability and consistency of your chiral APIs, meeting even the most demanding purification needs. With scalability from hundreds of kilograms to tons, our SMB system provides flexibility and reliability while reducing costs and environmental impact through decreased solvent use and continuous processing. Learn more about our comprehensive chromatography services and how we can select the right technique for your project: https://lnkd.in/eYwpU2dM #WuXiSTA